9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Status:
Recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination
with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers.
The names of the study drug(s) involved in this study are:
- 9-ING-41 (a GSK-3β inhibitor)
- Carboplatin chemotherapy